查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2129238

去細胞生物材料市場預測至2034年－全球分析（依生物材料原料、組織來源、去細胞方法、生物材料形態、基質組成、加工與改質、應用、終端使用者和地區分類）

Decellularized Biomaterials Market Forecasts To 2034 - Global Analysis By Biomaterial Source, Tissue Source, Decellularization Method, Biomaterial Form, Matrix Composition, Processing and Modification, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球去細胞生物材料市場規模將達到 36 億美元，並在預測期內以 12.4% 的複合年成長率成長，到 2034 年將達到 92 億美元。

隨著去細胞生物材料在再生醫學、組織工程、傷口護理和其他生物醫學領域的重要性日益凸顯，其市場正在不斷擴張。去細胞化是指從生物組織中移除細胞及其相關成分，同時保留細胞外基質框架的過程，而細胞外基質框架對於有效的細胞間相互作用和組織修復至關重要。人們對生物相容性支架材料日益成長的興趣、再生醫學研究的進展以及組織處理方法的改進，都推動了市場的發展。源自人類和動物組織的材料正被探索用於皮膚修復、心血管修復、整形外科和人工器官等領域。預計對生物技術投資的增加、個人化醫療的日益普及以及再生醫學的持續進步將進一步擴大市場機會。

慢性疾病和組織損傷性疾病的盛行率增加

慢性疾病、創傷、嚴重燒燙傷和組織損傷的日益加重，推動了對促進組織重建和癒合的創新解決方案的需求。皮膚、骨骼、心血管結構和其他組織的損傷通常需要先進的再生醫學方法，從而為去細胞生物材料創造有利環境。這些材料作為組織修復支架正日益受到關注，因為它們能夠保留必要的細胞外基質結構和生物特性。人口老化進一步增加了退化性疾病和複雜醫療干預的發生率。因此，隨著對改善癒合效果和功能恢復的需求不斷成長，醫學研究人員和醫療保健專業人員正在積極探索基於去細胞生物材料的治療方案。

高昂的製造和加工成本

高昂的生產和加工要求是去細胞生物材料市場的主要限制因素。生產通常需要精密的設備、專門的設施、組織採集、滅菌、保存以及全面的品質評估。在不損傷細胞外基質的情況下有效去除細胞需要精確控制的工藝，這增加了運作和人事費用。組織來源、保存、污染預防和生物材料表徵等相關成本進一步推高了整體生產成本。與某些合成生物材料相比，這些產品的製造成本可能更高，使其難以廣泛應用。成本因素會產生重大影響，尤其對於預算有限的醫療機構和製造商，以及新興醫療市場而言。

策略聯盟和進入新興市場

建立夥伴關係並進入新興醫療保健市場，預計將為脫細胞生物材料產業開闢新的成長途徑。生技公司、醫院、大學和生物材料製造商之間的合作，可以整合各自在組織處理、細胞科學、產品開發、生產製造和臨床研究方面的優勢。此類夥伴關係將加速生物材料的檢驗，並有助於推動其從實驗研究到商業性醫療應用的轉化。同時，新興經濟體醫療保健支出的成長、臨床基礎設施的完善以及人們對再生醫學認知的提高，都將支撐未來的需求。那些建立區域合作夥伴關係、加強供應鏈和分銷管道並提供經濟可行的生物材料解決方案的公司，將能夠抓住不斷成長的醫療保健市場中的商機。

臨床安全性和長期療效的潛在問題

長期安全性和性能的不確定性可能會阻礙去細胞生醫材料的廣泛應用。雖然去細胞處理旨在降低免疫反應，但殘留的細胞成分、加工化學物質或污染物若處理不當，仍可能造成潛在的安全隱患。支架的分解、重塑、機械穩定性以及與周圍組織的整合方面的差異也會影響長期臨床療效。某些應用需要大量證據來證明其長期耐久性和持續的治療效果。意外併發症和臨床證據不足會導致監管批准延遲，並削弱醫生的信心。因此，企業在驗證新型生物材料產品的安全性和有效性時，可能面臨更高的成本和更長的研發週期。

新型冠狀病毒（COVID-19）的影響：

新冠疫情透過擾亂醫療供應鏈、機構採購、實驗室准入、生產活動和生物醫學研究，暫時限制了去細胞生物材料市場的發展。旅行限制、運輸延誤、勞動力短缺和研究能力下降影響了生物材料的開發和臨床試驗進展。生物基質和關鍵實驗室資源的短缺，以及物流方面的挑戰，進一步加劇了研發和生產活動的複雜性。同時，疫情也凸顯了再生醫學、生物醫學創新和具有韌性的醫療供應鏈體系的重要性。總體而言，儘管新冠疫情帶來了短期市場挑戰，但也促進了研究合作的加強、供應鏈韌性的提升以及未來生物材料創新的發展。

在預測期內，「水凝膠材料」細分市場預計將佔據最大的市場佔有率。

預計在預測期內，水凝膠基材料將佔據最大的市場佔有率。源自去細胞基質的水凝膠能夠提供水合的、生物學上適宜的3D環境，從而保留重要的細胞外基質訊號和結構。這些特性促進細胞黏附、增生、分化和組織重塑。其可注射的特性使其能夠靈活地進行微創手術，並適應複雜或不規則的組織部位。因此，水凝膠基去細胞材料在再生醫學、傷口修復、控釋系統和生物製造等領域得到了廣泛的研究。親和性進一步拓展了其在特殊組織工程應用中的潛力。

在預測期內，神經病學領域預計將呈現最高的複合年成長率。

在預測期內，神經學領域預計將呈現最高的成長率。隨著神經組織工程研究的不斷深入，人們對用於神經系統的去細胞生物材料的興趣日益濃厚。這些材料保留了細胞外基質的特性，並能提供促進神經細胞黏附、遷移、生長和組織修復的生物訊號。研究人員正在探索將這些材料用於周邊神經修復、神經再生以及開發用於複雜神經系統應用的支架。去細胞基質能夠保留組織特異性的生化特性，使其成為仿生再生領域極具前景的平台。幹細胞、水凝膠配方和生物製造技術的持續進步有望拓寬這些材料在神經科學領域的應用範圍，並加速開發用於修復神經和神經組織的創新再生解決方案。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率，這得益於其完善的醫療保健體系、活躍的再生醫學研究以及組織工程和細胞外基質技術的蓬勃發展。該地區擁有眾多生物材料生產商、組織處理設施、專業醫療機構和學術研究中心，這些機構正在推動技術進步和臨床應用。去細胞支架在傷口護理、組織修復、整形外科重組和心血管外科等領域的廣泛應用也促進了該地區的需求。憑藉強大的臨床能力、完善的研究基礎設施和成熟的商業化管道，北美有望繼續保持其在去細胞生物材料市場的主導地位。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率。醫療基礎設施的快速發展、醫療投資的不斷成長以及對再生醫學日益成長的關注，全部區域創造了巨大的發展機會。中國、日本、韓國和印度的組織工程、生物材料和再生醫學研發工作正在穩步推進。組織修復、傷口管理、整形外科手術和心血管應用等領域先進解決方案的日益普及，也推動了市場擴張。除了該地區生物技術能力的提升，醫院、研究機構和生物材料開發公司之間夥伴關係的加強也促進了創新和商業化。因此，亞太地區預計將迎來快速的市場成長。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域分類
    • 根據客戶要求，我們可以提供主要國家和地區的市場估算和預測，以及複合年成長率（註：需經可行性確認）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要公司市佔率分析
  • 產品基準評效和效能比較

第5章：全球脫細胞生物材料市場：依原料分類

  • 人類來源的生物材料
  • 動物源性生物材料
  • 植物來源生物材料

第6章：全球脫細胞生物材料市場：依組織來源分類

  • 皮膚和真皮組織
  • 骨組織
  • 軟骨組織
  • 肌腱和韌帶組織
  • 骨骼肌組織
  • 脂肪組織
  • 血管組織
  • 心臟組織
  • 神經組織
  • 肝組織
  • 腎臟組織
  • 肺組織
  • 胰臟組織
  • 腸組織
  • 角膜和眼組織

第7章 全球去細胞生物材料市場：以去細胞法分類

  • 物理方法
  • 化學方法
  • 酵素法
  • 複合方法

第8章：全球脫細胞生物材料市場：以生物材料形式分類

  • 脫細胞組織片和膜
  • 去細胞組織粉末
  • 去細胞水凝膠
  • 去細胞支架
  • 脫細胞組織顆粒
  • 脫細胞生物墨水
  • 去細胞ECM溶液

第9章：全球去細胞生物材料市場：依基質成分分類

  • 富含膠原蛋白的生物材料
  • 富含彈性蛋白的生物材料
  • 富含Glico的生物材料
  • 富含蛋白聚醣的生物材料
  • 富含纖連蛋白的生物材料
  • 富含層粘連蛋白的生物材料
  • 多成分細胞外基質生物材料

第10章：全球脫細胞生物材料市場：依加工改質方法分類

  • 天然來源的去細胞生物材料
  • 交聯脫細胞生物材料
  • 功能化去細胞生物材料
  • 鈣化和去細胞生物材料
  • 複合脫細胞生物材料

第11章 全球去細胞生物材料市場：依治療領域分類

  • 整形外科和肌肉骨骼系統
  • 心血管系統
  • 皮膚病學和創傷護理
  • 神經系統
  • 眼科
  • 肝
  • 腎
  • 肺
  • 消化器官系統
  • 牙科和口腔健康

第12章 全球脫細胞生物材料市場：依給藥途徑分類

  • 嵌入式
  • 注射藥物
  • 外用

第13章 全球脫細胞生物材料市場：依應用領域分類

  • 組織工程
  • 創傷治療
  • 器官修復與再生
  • 細胞培養
  • 藥物輸送
  • 藥物發現與篩檢
  • 疾病模型
  • 3D生物列印
  • 植入式醫療設備

第14章 全球脫細胞生物材料市場：依最終用戶分類

  • 醫院和診所
  • 學術和研究機構
  • 生物技術和製藥公司
  • 醫療設備製造商
  • 受託研究機構
  • 組織庫和生物庫

第15章 全球脫細胞生物材料市場：依地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第16章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第17章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第18章：公司簡介

  • Integra LifeSciences Corporation
  • LifeNet Health
  • MTF Biologics
  • Cook Biotech Inc.
  • Stryker Corporation
  • Zimmer Biomet Holdings, Inc.
  • Medtronic plc
  • Aroa Biosurgery Limited
  • RTI Surgical Holdings, Inc.
  • CorMatrix Cardiovascular, Inc.
  • Tissue Regenix Group plc
  • Humacyte, Inc.
  • AxoGen, Inc.
  • Miromatrix Medical Inc.
  • Kerecis
  • TELA Bio, Inc.
  • Smith+Nephew plc
  • B. Braun Melsungen AG
Product Code: SMRC39365

According to Stratistics MRC, the Global Decellularized Biomaterials Market is accounted for $3.6 billion in 2026 and is expected to reach $9.2 billion by 2034 growing at a CAGR of 12.4% during the forecast period. The decellularized biomaterials market is expanding as these biomaterials gain importance in regenerative medicine, tissue engineering, wound treatment, and other biomedical fields. Decellularization eliminates cells and associated components from biological tissues while maintaining the extracellular matrix framework required for effective cellular interaction and tissue repair. Rising interest in biocompatible scaffolds, progress in regenerative medicine research, and improvements in tissue-processing methods are contributing to market development. Materials obtained from human and animal tissues are being explored for skin regeneration, cardiovascular repair, orthopedic applications, and engineered organs. Increasing biotechnology investments, growing adoption of personalized healthcare, and ongoing advances in regenerative therapies are expected to strengthen market opportunities.

Market Dynamics:

Driver:

Increasing Prevalence of Chronic and Tissue-Damaging Conditions

A growing burden of chronic illnesses, traumatic injuries, severe burns, and tissue disorders is driving demand for innovative solutions that facilitate tissue reconstruction and healing. Damage to skin, bone, cardiovascular structures, and other tissues often requires advanced regenerative approaches, creating a favorable environment for decellularized biomaterials. Because these materials can preserve essential extracellular matrix structures and biological characteristics, they are increasingly examined as scaffolds for supporting tissue restoration. Population aging further increases the occurrence of degenerative diseases and complex medical interventions. The need for improved healing outcomes and functional recovery is therefore encouraging healthcare researchers and providers to explore decellularized biomaterial-based therapeutic solutions.

Restraint:

High Manufacturing and Processing Costs

Expensive manufacturing and processing requirements represent a significant limitation for the decellularized biomaterials market. Production often involves sophisticated equipment, specialized facilities, biological tissue collection, sterilization, preservation, and comprehensive quality assessment. Achieving effective cell removal without damaging the extracellular matrix requires precisely controlled processes, increasing operational and workforce costs. Expenses related to tissue procurement, storage, contamination prevention, and biomaterial characterization further raise overall production costs. Compared with some synthetic biomaterials, these products may therefore have higher manufacturing expenses, making widespread adoption more challenging. Cost considerations can particularly affect healthcare organizations and manufacturers operating within constrained budgets or developing healthcare markets.

Opportunity:

Strategic Collaborations and Expansion into Emerging Markets

Partnerships and expansion into developing healthcare markets can generate new growth avenues for the decellularized biomaterials industry. Collaboration between biotechnology firms, hospitals, universities, and biomaterial manufacturers can bring together capabilities in tissue processing, cellular science, product development, manufacturing, and clinical research. These partnerships can help accelerate biomaterial validation and support the transition from experimental research to commercial healthcare applications. Meanwhile, rising healthcare expenditure, improving clinical infrastructure, and increasing awareness of regenerative medicine in emerging economies can support future demand. Companies that develop regional collaborations, strengthen supply and distribution channels, and offer economically viable biomaterial solutions could capture opportunities across growing healthcare markets.

Threat:

Potential Clinical Safety and Long-Term Performance Concerns

Uncertainty regarding long-term safety and performance can threaten broader adoption of decellularized biomaterials. Although decellularization is intended to reduce immune reactions, residual cellular components, processing chemicals, or contaminants may create potential safety concerns if not adequately controlled. Differences in scaffold degradation, remodeling, mechanical stability, and integration with surrounding tissues may also influence long-term clinical outcomes. Some applications require extensive evidence to demonstrate durability and consistent therapeutic performance over extended periods. Unexpected complications or insufficient clinical evidence could delay regulatory approvals and reduce physician confidence. Consequently, companies may face increased costs and longer development timelines when establishing the safety and effectiveness of new biomaterial products.

Covid-19 Impact:

COVID-19 temporarily constrained the decellularized biomaterials market through interruptions in medical supply chains, tissue procurement, laboratory access, manufacturing activities, and biomedical research. Restrictions on movement, transportation delays, workforce limitations, and reduced research capacity affected the progress of biomaterial development and clinical investigations. Shortages and logistical challenges involving biological matrices and essential laboratory resources further complicated research and production activities. At the same time, the pandemic highlighted the importance of regenerative medicine, biomedical innovation, and resilient healthcare supply systems. Overall, COVID-19 caused near-term market challenges but also encouraged stronger research collaboration, supply-chain resilience, and future biomaterial innovation.

The Hydrogel-Based Materials segment is expected to be the largest during the forecast period

The Hydrogel-Based Materials segment is expected to account for the largest market share during the forecast period, Decellularized matrix-derived hydrogels provide a hydrated and biologically relevant three-dimensional environment that can preserve key extracellular matrix signals and structures. These characteristics can encourage cellular adhesion, growth, differentiation, and tissue reconstruction. Their ability to be delivered in injectable form provides flexibility for minimally invasive procedures and enables adaptation to complex or irregular tissue sites. Consequently, hydrogel-based decellularized materials are being explored extensively for regenerative therapies, wound repair, controlled delivery systems, and biofabrication. Their compatibility with bioprinting and cell-based approaches further expands their potential for specialized tissue engineering applications.

The Neurological segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Neurological segment is predicted to witness the highest growth rate, Increasing research into neural tissue engineering is creating greater interest in decellularized biomaterials for neurological applications. Their preserved extracellular matrix characteristics can provide supportive biological signals for neural cell adhesion, movement, growth, and tissue restoration. Researchers are exploring these materials for peripheral nerve repair, neural regeneration, and scaffold development for complex neurological applications. The ability of decellularized matrices to retain tissue-specific biochemical properties makes them promising platforms for biomimetic regeneration. Continued advances involving stem cells, hydrogel formulations, and biofabrication techniques could broaden their use in neurological medicine and accelerate development of innovative regenerative solutions for nerve and neural tissue repair.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, supported by well-developed healthcare systems, substantial regenerative medicine research, and growing activity in tissue engineering and extracellular matrix-based technologies. The region has a strong presence of biomaterial manufacturers, tissue-processing organizations, specialized healthcare facilities, and academic research centers, which facilitates technological advancement and clinical adoption. Increasing application of decellularized scaffolds in wound treatment, tissue repair, orthopedic reconstruction, and cardiovascular procedures is also contributing to regional demand. Strong clinical capabilities, research infrastructure, and established commercialization pathways are expected to maintain North America's prominent position in the decellularized biomaterials market.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, Rapid improvements in healthcare infrastructure, increasing healthcare investment, and growing emphasis on regenerative medicine are creating strong opportunities across the region. China, Japan, South Korea, and India are advancing research and development in tissue engineering, biomaterials, and regenerative therapies. Greater adoption of advanced solutions for tissue repair, wound management, orthopedic procedures, and cardiovascular applications is also encouraging market expansion. The development of regional biotechnology capabilities, combined with stronger partnerships among hospitals, research organizations, and biomaterial developers, is supporting innovation and commercialization. Consequently, Asia Pacific is positioned for rapid market growth.

Key players in the market

Some of the key players in Decellularized Biomaterials Market include Integra LifeSciences Corporation, LifeNet Health, MTF Biologics, Cook Biotech Inc., Stryker Corporation, Zimmer Biomet Holdings, Inc., Medtronic plc, Aroa Biosurgery Limited, RTI Surgical Holdings, Inc., CorMatrix Cardiovascular, Inc., Tissue Regenix Group plc, Humacyte, Inc., AxoGen, Inc., Miromatrix Medical Inc., Kerecis, TELA Bio, Inc., Smith+Nephew plc and B. Braun Melsungen AG.

Key Developments:

In May 2026, Cook Medical and Purdue University announced a new five-year Master Sponsored Research and Collaboration Agreement. The partnership establishes a framework for joint research, testing, and development of innovative medical technologies, including advanced medical-device manufacturing and materials science.

In June 2026, LEPU Medical reported an international collaboration involving Bakoulev National Medical Research Center for Cardiovascular Surgery and Chinese cardiovascular experts during the first Russia implantation of its biodegradable occluders.

In March 2026, Terumo BCT entered into a collaboration with Taiwan Bio Therapeutics to transition regulatory T-cell manufacturing to the automated Quantum Flex platform. The work combines Taiwan Bio's Treg manufacturing expertise with Terumo's automated cell-expansion technology to establish a more scalable and standardized process for cell-based therapy development.

Biomaterial Sources Covered:

  • Human-Derived Biomaterials
  • Animal-Derived Biomaterials
  • Plant-Derived Biomaterials

Tissue Sources Covered:

  • Skin and Dermal Tissue
  • Bone Tissue
  • Cartilage Tissue
  • Tendon and Ligament Tissue
  • Skeletal Muscle Tissue
  • Adipose Tissue
  • Vascular Tissue
  • Cardiac Tissue
  • Nerve Tissue
  • Liver Tissue
  • Kidney Tissue
  • Lung Tissue
  • Pancreatic Tissue
  • Intestinal Tissue
  • Corneal and Ocular Tissue

Decellularization Methods Covered:

  • Physical Methods
  • Chemical Methods
  • Enzymatic Methods
  • Combined Methods

Biomaterial Forms Covered:

  • Decellularized Tissue Sheets and Membranes
  • Decellularized Tissue Powders
  • Decellularized Hydrogels
  • Decellularized Scaffolds
  • Decellularized Tissue Particulates
  • Decellularized Bioinks
  • Decellularized ECM Solutions

Matrix Compositions Covered:

  • Collagen-Rich Biomaterials
  • Elastin-Rich Biomaterials
  • Glycosaminoglycan-Rich Biomaterials
  • Proteoglycan-Rich Biomaterials
  • Fibronectin-Rich Biomaterials
  • Laminin-Rich Biomaterials
  • Multi-Component ECM Biomaterials

Processing and Modifications Covered:

  • Native Decellularized Biomaterials
  • Crosslinked Decellularized Biomaterials
  • Functionalized Decellularized Biomaterials
  • Mineralized Decellularized Biomaterials
  • Composite Decellularized Biomaterials

Therapeutic Areas Covered:

  • Orthopedic and Musculoskeletal
  • Cardiovascular
  • Dermatology and Wound Care
  • Neurological
  • Ophthalmic
  • Hepatic
  • Renal
  • Pulmonary
  • Gastrointestinal
  • Dental and Oral

Route of Administrations Covered:

  • Implantable
  • Injectable
  • Topical

Applications Covered:

  • Tissue Engineering
  • Wound Healing
  • Organ Repair and Regeneration
  • Cell Culture
  • Drug Delivery
  • Drug Discovery and Screening
  • Disease Modeling
  • 3D Bioprinting
  • Implantable Medical Devices

End Users Covered:

  • Hospitals and Clinics
  • Academic and Research Institutions
  • Biotechnology and Pharmaceutical Companies
  • Medical Device Companies
  • Contract Research Organizations
  • Tissue Banks and Biobanks

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Decellularized Biomaterials Market, By Biomaterial Source

  • 5.1 Human-Derived Biomaterials
  • 5.2 Animal-Derived Biomaterials
  • 5.3 Plant-Derived Biomaterials

6 Global Decellularized Biomaterials Market, By Tissue Source

  • 6.1 Skin and Dermal Tissue
  • 6.2 Bone Tissue
  • 6.3 Cartilage Tissue
  • 6.4 Tendon and Ligament Tissue
  • 6.5 Skeletal Muscle Tissue
  • 6.6 Adipose Tissue
  • 6.7 Vascular Tissue
  • 6.8 Cardiac Tissue
  • 6.9 Nerve Tissue
  • 6.10 Liver Tissue
  • 6.11 Kidney Tissue
  • 6.12 Lung Tissue
  • 6.13 Pancreatic Tissue
  • 6.14 Intestinal Tissue
  • 6.15 Corneal and Ocular Tissue

7 Global Decellularized Biomaterials Market, By Decellularization Method

  • 7.1 Physical Methods
  • 7.2 Chemical Methods
  • 7.3 Enzymatic Methods
  • 7.4 Combined Methods

8 Global Decellularized Biomaterials Market, By Biomaterial Form

  • 8.1 Decellularized Tissue Sheets and Membranes
  • 8.2 Decellularized Tissue Powders
  • 8.3 Decellularized Hydrogels
  • 8.4 Decellularized Scaffolds
  • 8.5 Decellularized Tissue Particulates
  • 8.6 Decellularized Bioinks
  • 8.7 Decellularized ECM Solutions

9 Global Decellularized Biomaterials Market, By Matrix Composition

  • 9.1 Collagen-Rich Biomaterials
  • 9.2 Elastin-Rich Biomaterials
  • 9.3 Glycosaminoglycan-Rich Biomaterials
  • 9.4 Proteoglycan-Rich Biomaterials
  • 9.5 Fibronectin-Rich Biomaterials
  • 9.6 Laminin-Rich Biomaterials
  • 9.7 Multi-Component ECM Biomaterials

10 Global Decellularized Biomaterials Market, By Processing and Modification

  • 10.1 Native Decellularized Biomaterials
  • 10.2 Crosslinked Decellularized Biomaterials
  • 10.3 Functionalized Decellularized Biomaterials
  • 10.4 Mineralized Decellularized Biomaterials
  • 10.5 Composite Decellularized Biomaterials

11 Global Decellularized Biomaterials Market, By Therapeutic Area

  • 11.1 Orthopedic and Musculoskeletal
  • 11.2 Cardiovascular
  • 11.3 Dermatology and Wound Care
  • 11.4 Neurological
  • 11.5 Ophthalmic
  • 11.6 Hepatic
  • 11.7 Renal
  • 11.8 Pulmonary
  • 11.9 Gastrointestinal
  • 11.10 Dental and Oral

12 Global Decellularized Biomaterials Market, By Route of Administration

  • 12.1 Implantable
  • 12.2 Injectable
  • 12.3 Topical

13 Global Decellularized Biomaterials Market, By Application

  • 13.1 Tissue Engineering
  • 13.2 Wound Healing
  • 13.3 Organ Repair and Regeneration
  • 13.4 Cell Culture
  • 13.5 Drug Delivery
  • 13.6 Drug Discovery and Screening
  • 13.7 Disease Modeling
  • 13.8 3D Bioprinting
  • 13.9 Implantable Medical Devices

14 Global Decellularized Biomaterials Market, By End User

  • 14.1 Hospitals and Clinics
  • 14.2 Academic and Research Institutions
  • 14.3 Biotechnology and Pharmaceutical Companies
  • 14.4 Medical Device Companies
  • 14.5 Contract Research Organizations
  • 14.6 Tissue Banks and Biobanks

15 Global Decellularized Biomaterials Market, By Geography

  • 15.1 North America
    • 15.1.1 United States
    • 15.1.2 Canada
    • 15.1.3 Mexico
  • 15.2 Europe
    • 15.2.1 United Kingdom
    • 15.2.2 Germany
    • 15.2.3 France
    • 15.2.4 Italy
    • 15.2.5 Spain
    • 15.2.6 Netherlands
    • 15.2.7 Belgium
    • 15.2.8 Sweden
    • 15.2.9 Switzerland
    • 15.2.10 Poland
    • 15.2.11 Rest of Europe
  • 15.3 Asia Pacific
    • 15.3.1 China
    • 15.3.2 Japan
    • 15.3.3 India
    • 15.3.4 South Korea
    • 15.3.5 Australia
    • 15.3.6 Indonesia
    • 15.3.7 Thailand
    • 15.3.8 Malaysia
    • 15.3.9 Singapore
    • 15.3.10 Vietnam
    • 15.3.11 Rest of Asia Pacific
  • 15.4 South America
    • 15.4.1 Brazil
    • 15.4.2 Argentina
    • 15.4.3 Colombia
    • 15.4.4 Chile
    • 15.4.5 Peru
    • 15.4.6 Rest of South America
  • 15.5 Rest of the World (RoW)
    • 15.5.1 Middle East
      • 15.5.1.1 Saudi Arabia
      • 15.5.1.2 United Arab Emirates
      • 15.5.1.3 Qatar
      • 15.5.1.4 Israel
      • 15.5.1.5 Rest of Middle East
    • 15.5.2 Africa
      • 15.5.2.1 South Africa
      • 15.5.2.2 Egypt
      • 15.5.2.3 Morocco
      • 15.5.2.4 Rest of Africa

16 Strategic Market Intelligence

  • 16.1 Industry Value Network and Supply Chain Assessment
  • 16.2 White-Space and Opportunity Mapping
  • 16.3 Product Evolution and Market Life Cycle Analysis
  • 16.4 Channel, Distributor, and Go-to-Market Assessment

17 Industry Developments and Strategic Initiatives

  • 17.1 Mergers and Acquisitions
  • 17.2 Partnerships, Alliances, and Joint Ventures
  • 17.3 New Product Launches and Certifications
  • 17.4 Capacity Expansion and Investments
  • 17.5 Other Strategic Initiatives

18 Company Profiles

  • 18.1 Integra LifeSciences Corporation
  • 18.2 LifeNet Health
  • 18.3 MTF Biologics
  • 18.4 Cook Biotech Inc.
  • 18.5 Stryker Corporation
  • 18.6 Zimmer Biomet Holdings, Inc.
  • 18.7 Medtronic plc
  • 18.8 Aroa Biosurgery Limited
  • 18.9 RTI Surgical Holdings, Inc.
  • 18.10 CorMatrix Cardiovascular, Inc.
  • 18.11 Tissue Regenix Group plc
  • 18.12 Humacyte, Inc.
  • 18.13 AxoGen, Inc.
  • 18.14 Miromatrix Medical Inc.
  • 18.15 Kerecis
  • 18.16 TELA Bio, Inc.
  • 18.17 Smith+Nephew plc
  • 18.18 B. Braun Melsungen AG

List of Tables

  • Table 1 Global Decellularized Biomaterials Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Decellularized Biomaterials Market Outlook, By Biomaterial Source (2023-2034) ($MN)
  • Table 3 Global Decellularized Biomaterials Market Outlook, By Human-Derived Biomaterials (2023-2034) ($MN)
  • Table 4 Global Decellularized Biomaterials Market Outlook, By Animal-Derived Biomaterials (2023-2034) ($MN)
  • Table 5 Global Decellularized Biomaterials Market Outlook, By Plant-Derived Biomaterials (2023-2034) ($MN)
  • Table 6 Global Decellularized Biomaterials Market Outlook, By Tissue Source (2023-2034) ($MN)
  • Table 7 Global Decellularized Biomaterials Market Outlook, By Skin and Dermal Tissue (2023-2034) ($MN)
  • Table 8 Global Decellularized Biomaterials Market Outlook, By Bone Tissue (2023-2034) ($MN)
  • Table 9 Global Decellularized Biomaterials Market Outlook, By Cartilage Tissue (2023-2034) ($MN)
  • Table 10 Global Decellularized Biomaterials Market Outlook, By Tendon and Ligament Tissue (2023-2034) ($MN)
  • Table 11 Global Decellularized Biomaterials Market Outlook, By Skeletal Muscle Tissue (2023-2034) ($MN)
  • Table 12 Global Decellularized Biomaterials Market Outlook, By Adipose Tissue (2023-2034) ($MN)
  • Table 13 Global Decellularized Biomaterials Market Outlook, By Vascular Tissue (2023-2034) ($MN)
  • Table 14 Global Decellularized Biomaterials Market Outlook, By Cardiac Tissue (2023-2034) ($MN)
  • Table 15 Global Decellularized Biomaterials Market Outlook, By Nerve Tissue (2023-2034) ($MN)
  • Table 16 Global Decellularized Biomaterials Market Outlook, By Liver Tissue (2023-2034) ($MN)
  • Table 17 Global Decellularized Biomaterials Market Outlook, By Kidney Tissue (2023-2034) ($MN)
  • Table 18 Global Decellularized Biomaterials Market Outlook, By Lung Tissue (2023-2034) ($MN)
  • Table 19 Global Decellularized Biomaterials Market Outlook, By Pancreatic Tissue (2023-2034) ($MN)
  • Table 20 Global Decellularized Biomaterials Market Outlook, By Intestinal Tissue (2023-2034) ($MN)
  • Table 21 Global Decellularized Biomaterials Market Outlook, By Corneal and Ocular Tissue (2023-2034) ($MN)
  • Table 22 Global Decellularized Biomaterials Market Outlook, By Decellularization Method (2023-2034) ($MN)
  • Table 23 Global Decellularized Biomaterials Market Outlook, By Physical Methods (2023-2034) ($MN)
  • Table 24 Global Decellularized Biomaterials Market Outlook, By Chemical Methods (2023-2034) ($MN)
  • Table 25 Global Decellularized Biomaterials Market Outlook, By Enzymatic Methods (2023-2034) ($MN)
  • Table 26 Global Decellularized Biomaterials Market Outlook, By Combined Methods (2023-2034) ($MN)
  • Table 27 Global Decellularized Biomaterials Market Outlook, By Biomaterial Form (2023-2034) ($MN)
  • Table 28 Global Decellularized Biomaterials Market Outlook, By Decellularized Tissue Sheets and Membranes (2023-2034) ($MN)
  • Table 29 Global Decellularized Biomaterials Market Outlook, By Decellularized Tissue Powders (2023-2034) ($MN)
  • Table 30 Global Decellularized Biomaterials Market Outlook, By Decellularized Hydrogels (2023-2034) ($MN)
  • Table 31 Global Decellularized Biomaterials Market Outlook, By Decellularized Scaffolds (2023-2034) ($MN)
  • Table 32 Global Decellularized Biomaterials Market Outlook, By Decellularized Tissue Particulates (2023-2034) ($MN)
  • Table 33 Global Decellularized Biomaterials Market Outlook, By Decellularized Bioinks (2023-2034) ($MN)
  • Table 34 Global Decellularized Biomaterials Market Outlook, By Decellularized ECM Solutions (2023-2034) ($MN)
  • Table 35 Global Decellularized Biomaterials Market Outlook, By Matrix Composition (2023-2034) ($MN)
  • Table 36 Global Decellularized Biomaterials Market Outlook, By Collagen-Rich Biomaterials (2023-2034) ($MN)
  • Table 37 Global Decellularized Biomaterials Market Outlook, By Elastin-Rich Biomaterials (2023-2034) ($MN)
  • Table 38 Global Decellularized Biomaterials Market Outlook, By Glycosaminoglycan-Rich Biomaterials (2023-2034) ($MN)
  • Table 39 Global Decellularized Biomaterials Market Outlook, By Proteoglycan-Rich Biomaterials (2023-2034) ($MN)
  • Table 40 Global Decellularized Biomaterials Market Outlook, By Fibronectin-Rich Biomaterials (2023-2034) ($MN)
  • Table 41 Global Decellularized Biomaterials Market Outlook, By Laminin-Rich Biomaterials (2023-2034) ($MN)
  • Table 42 Global Decellularized Biomaterials Market Outlook, By Multi-Component ECM Biomaterials (2023-2034) ($MN)
  • Table 43 Global Decellularized Biomaterials Market Outlook, By Processing and Modification (2023-2034) ($MN)
  • Table 44 Global Decellularized Biomaterials Market Outlook, By Native Decellularized Biomaterials (2023-2034) ($MN)
  • Table 45 Global Decellularized Biomaterials Market Outlook, By Crosslinked Decellularized Biomaterials (2023-2034) ($MN)
  • Table 46 Global Decellularized Biomaterials Market Outlook, By Functionalized Decellularized Biomaterials (2023-2034) ($MN)
  • Table 47 Global Decellularized Biomaterials Market Outlook, By Mineralized Decellularized Biomaterials (2023-2034) ($MN)
  • Table 48 Global Decellularized Biomaterials Market Outlook, By Composite Decellularized Biomaterials (2023-2034) ($MN)
  • Table 49 Global Decellularized Biomaterials Market Outlook, By Therapeutic Area (2023-2034) ($MN)
  • Table 50 Global Decellularized Biomaterials Market Outlook, By Orthopedic and Musculoskeletal (2023-2034) ($MN)
  • Table 51 Global Decellularized Biomaterials Market Outlook, By Cardiovascular (2023-2034) ($MN)
  • Table 52 Global Decellularized Biomaterials Market Outlook, By Dermatology and Wound Care (2023-2034) ($MN)
  • Table 53 Global Decellularized Biomaterials Market Outlook, By Neurological (2023-2034) ($MN)
  • Table 54 Global Decellularized Biomaterials Market Outlook, By Ophthalmic (2023-2034) ($MN)
  • Table 55 Global Decellularized Biomaterials Market Outlook, By Hepatic (2023-2034) ($MN)
  • Table 56 Global Decellularized Biomaterials Market Outlook, By Renal (2023-2034) ($MN)
  • Table 57 Global Decellularized Biomaterials Market Outlook, By Pulmonary (2023-2034) ($MN)
  • Table 58 Global Decellularized Biomaterials Market Outlook, By Gastrointestinal (2023-2034) ($MN)
  • Table 59 Global Decellularized Biomaterials Market Outlook, By Dental and Oral (2023-2034) ($MN)
  • Table 60 Global Decellularized Biomaterials Market Outlook, By Route of Administration (2023-2034) ($MN)
  • Table 61 Global Decellularized Biomaterials Market Outlook, By Implantable (2023-2034) ($MN)
  • Table 62 Global Decellularized Biomaterials Market Outlook, By Injectable (2023-2034) ($MN)
  • Table 63 Global Decellularized Biomaterials Market Outlook, By Topical (2023-2034) ($MN)
  • Table 64 Global Decellularized Biomaterials Market Outlook, By Application (2023-2034) ($MN)
  • Table 65 Global Decellularized Biomaterials Market Outlook, By Tissue Engineering (2023-2034) ($MN)
  • Table 66 Global Decellularized Biomaterials Market Outlook, By Wound Healing (2023-2034) ($MN)
  • Table 67 Global Decellularized Biomaterials Market Outlook, By Organ Repair and Regeneration (2023-2034) ($MN)
  • Table 68 Global Decellularized Biomaterials Market Outlook, By Cell Culture (2023-2034) ($MN)
  • Table 69 Global Decellularized Biomaterials Market Outlook, By Drug Delivery (2023-2034) ($MN)
  • Table 70 Global Decellularized Biomaterials Market Outlook, By Drug Discovery and Screening (2023-2034) ($MN)
  • Table 71 Global Decellularized Biomaterials Market Outlook, By Disease Modeling (2023-2034) ($MN)
  • Table 72 Global Decellularized Biomaterials Market Outlook, By 3D Bioprinting (2023-2034) ($MN)
  • Table 73 Global Decellularized Biomaterials Market Outlook, By Implantable Medical Devices (2023-2034) ($MN)
  • Table 74 Global Decellularized Biomaterials Market Outlook, By End User (2023-2034) ($MN)
  • Table 75 Global Decellularized Biomaterials Market Outlook, By Hospitals and Clinics (2023-2034) ($MN)
  • Table 76 Global Decellularized Biomaterials Market Outlook, By Academic and Research Institutions (2023-2034) ($MN)
  • Table 77 Global Decellularized Biomaterials Market Outlook, By Biotechnology and Pharmaceutical Companies (2023-2034) ($MN)
  • Table 78 Global Decellularized Biomaterials Market Outlook, By Medical Device Companies (2023-2034) ($MN)
  • Table 79 Global Decellularized Biomaterials Market Outlook, By Contract Research Organizations (2023-2034) ($MN)
  • Table 80 Global Decellularized Biomaterials Market Outlook, By Tissue Banks and Biobanks (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.